RE:Baxter Redaction and InterestIt makes sense to me that Baxter may take out Spectral at 90 patients. If what we are told is true, they are geared up to hit the road with PMX very shortly. Makes me think that they may want to control the stretch run... assuming one is required.
I also have a feeling that the little discussed Eden study may play a bigger role than anticipated in hitting this 150 number.